Shares of Abbott Laboratories (ABT) are rising and those of Reckitt Benckiser are gaining in London trading Friday, a day after a jury cleared the two infant formula makers of liability for a boy's debilitating intestinal disease.
The ruling by a Missouri state court jury Thursday is a rare legal win for Abbott Laboratories, maker of the Similac formula, and Reckitt, which produces the Mead Johnson formula, following their losses in similar trials involving necrotizing enterocolitis (NEC), a life-threatening disease that affects the colon and intestine.
"The decision reinforces what we, the medical community and regulatory bodies have said: that preterm infant nutrition products are safe, and there is no reliable scientific evidence that they cause or contribute to cause NEC," Abbott said in a statement to Investopedia.
Reckitt echoed those remarks in a press release Thursday.
"Today's verdict is consistent with the scientific consensus that there is no established causal link between the use of specialized preterm hospital nutrition products and NEC, and that where human milk is unavailable or when supplementation is necessary, specialized preterm hospital nutrition products can provide essential, lifesaving nutrition," Reckitt said.
"This is the first victory for the two companies in a NEC state case after Abbott was ordered to pay $495m in July in the Gill case and Reckitt's Mead Johnson $60m in March in the Watson case," UBS analysts wrote Friday.
Reckitt shares are up 8% in London trading Friday but have lost 7% this year. Abbott shares are rising 5% and have gained 8% in 2024.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。